Boehringer’s Nerandomilast Hits Primary Endpoint in Phase III FIBRONEER-ILD for Pulmonary Fibrosis Read more
Novartis Strengthens Cardiovascular Pipeline with $925 Million Anthos Therapeutics Acquisition Read more
Bio-Thera Solutions Signs Exclusive License Deal with Intas for BAT2506 Biosimilar in the U.S. Read more